-
市场
-
产品
-
资讯
-
Moo社区
-
课堂
-
查看更多
-
功能介绍
-
费用费用透明,无最低余额限制
投资选择、功能介绍、费用相关信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 浅色
Cathie Wood's Ark Funds Built Up Big Stakes in Crispr. The Stock Is Now Tumbling. -- Barrons.com
Cathie Wood's Ark Funds Built Up Big Stakes in Crispr. The Stock Is Now Tumbling. -- Barrons.com
By Jack Denton
Crispr Therapeutics stock was tumbling Wednesday, after the results of an experimental treatment from the gene-based medicine specialist underwhelmed investors.
That is bad news for high-profile investor Cathie Wood, whose Ark Investment Management recently bought shares in the biotech company for two of its actively managed exchange-traded funds (ETFs).
The ARK Innovation ETF (ARKK) and ARK Genomic Revolution ETF (ARKG) cumulatively bought up hundreds of thousands of shares of Crispr (ticker: CRSP) in the week leading up to its release of trial data on its gene-edited cancer drug, CTX110.
Crispr said Tuesday that "encouraging" phase-one results of the drug meant the company planned to expand its trial, with the next stage potentially leading to data for submission to regulators for approval.
But investors appeared underwhelmed by the results, which showed that just 36% of the 26 patients who received the drug had a complete response with no detectable cancer.
Crispr stock was down 6% in U.S. premarket trading Wednesday, as investors fretted over how the drug may fare against competitors. Shares rose in rival gene-editing biotechs like Editas Medicine (EDIT), which was 0.3% higher in the premarket, and Allogene Therapeutics (ALLO), which ticked up 0.2%.
Leading up to the release of Crispr's results, Wood's investment group bought up more than 700,000 Crispr shares valued around $100 each, according to Cathie's Ark, a website tracking ARK trades.
ARKK snapped up more than 513,000 shares of Crispr in trades made Oct. 8, Oct. 11, and Oct. 12, while ARKG bought more than 201,000 shares in trades on Oct. 8 and Oct. 11, according to data from Cathie's Ark.
Ark's holdings in the biotech group represented a market capitalization of $7.8 billion based on the stock's closing price Tuesday of $102.59.
After stunning performances in 2020, when ARKK's net asset value (NAV) grew 152% and ARKG's NAV surged 180%, both funds have failed to match the performance in 2021. ARKK's NAV is up 5% so far this year, while ARKG's NAV has declined 0.8%.
Write to Jack Denton at jack.denton@dowjones.com
By Jack Denton
杰克·丹顿(Jack Denton)著
Crispr Therapeutics stock was tumbling Wednesday, after the results of an experimental treatment from the gene-based medicine specialist underwhelmed investors.
周三,CRISPR治疗公司的股票暴跌,此前这家基于基因的医学专家的一项实验性治疗结果令投资者印象不佳。
That is bad news for high-profile investor Cathie Wood, whose Ark Investment Management recently bought shares in the biotech company for two of its actively managed exchange-traded funds (ETFs).
这对知名投资者凯西·伍德(Cathie Wood)来说是个坏消息,她的方舟投资管理公司(Ark Investment Management)最近为其两只积极管理的交易所交易基金(ETF)购买了这家生物技术公司的股票。
The ARK Innovation ETF (ARKK) and ARK Genomic Revolution ETF (ARKG) cumulatively bought up hundreds of thousands of shares of Crispr (ticker: CRSP) in the week leading up to its release of trial data on its gene-edited cancer drug, CTX110.
方舟创新ETF(ARKK)和方舟基因革命ETF(ARKG)在Crispr(股票代码:CRSP)公布其基因编辑抗癌药物CTX110的试验数据前一周累计买入数十万股。
Crispr said Tuesday that "encouraging" phase-one results of the drug meant the company planned to expand its trial, with the next stage potentially leading to data for submission to regulators for approval.
CRISPR周二表示,该药物的第一阶段结果“令人鼓舞”,这意味着该公司计划扩大试验范围,下一阶段可能会产生数据,提交监管机构审批。
But investors appeared underwhelmed by the results, which showed that just 36% of the 26 patients who received the drug had a complete response with no detectable cancer.
但投资者似乎对结果不以为然,结果显示,在接受药物治疗的26名患者中,只有36%的人完全有效,没有发现癌症。
Crispr stock was down 6% in U.S. premarket trading Wednesday, as investors fretted over how the drug may fare against competitors. Shares rose in rival gene-editing biotechs like Editas Medicine (EDIT), which was 0.3% higher in the premarket, and Allogene Therapeutics (ALLO), which ticked up 0.2%.
CRISPR的股价周三在美国盘前交易中下跌6%,投资者担心这种药物可能会如何对抗竞争对手。竞争对手基因编辑生物技术公司的股价上涨,如Editas Medicine(EDIT)和Allo(Allo),前者在盘前上涨0.3%,后者上涨0.2%。
Leading up to the release of Crispr's results, Wood's investment group bought up more than 700,000 Crispr shares valued around $100 each, according to Cathie's Ark, a website tracking ARK trades.
根据追踪方舟交易的网站Cathie‘s Ark的数据,在Crispr公布财报之前,伍德的投资集团买入了超过70万股Crispr股票,每股价值约100美元。
ARKK snapped up more than 513,000 shares of Crispr in trades made Oct. 8, Oct. 11, and Oct. 12, while ARKG bought more than 201,000 shares in trades on Oct. 8 and Oct. 11, according to data from Cathie's Ark.
根据凯茜方舟的数据,Arkk在10月8日、10月11日和10月12日的交易中抢购了超过51.3万股Crispr股票,而ARKG在10月8日和10月11日的交易中购买了超过20.1万股Crispr股票。
Ark's holdings in the biotech group represented a market capitalization of $7.8 billion based on the stock's closing price Tuesday of $102.59.
按照该股周二102.59美元的收盘价计算,方舟在这家生物科技集团的持股相当于78亿美元的市值。
After stunning performances in 2020, when ARKK's net asset value (NAV) grew 152% and ARKG's NAV surged 180%, both funds have failed to match the performance in 2021. ARKK's NAV is up 5% so far this year, while ARKG's NAV has declined 0.8%.
2020年Arkk的资产净值(NAV)增长152%,ARKG的资产净值飙升180%,在经历了令人惊叹的表现后,这两只基金在2021年的表现都未能与之匹敌。Arkk的资产净值今年迄今上涨了5%,而ArkG的资产净值下降了0.8%。
Write to Jack Denton at jack.denton@dowjones.com
写信给杰克·丹顿(Jack Denton),电子邮件:jack.denton@dowjones.com
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
风险及免责提示
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用浏览器的分享功能,分享给你的好友吧